Abbonarsi

Necrotizing Scleritis After Cosmetic Conjunctivectomy With Mitomycin C - 02/10/18

Doi : 10.1016/j.ajo.2018.07.008 
Yong Woo Ji a, b, Si Yoon Park a, Ji Won Jung c, Seonghee Choi a, Mutlaq Hamad Alotaibi a, d, R. Doyle Stulting e, David G. Hwang f, Kyoung Yul Seo a,
a Institute of Vision Research, Department of Ophthalmology, Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea 
b Department of Ophthalmology, National Health Insurance Service Ilsan Hospital, Goyang, South Korea 
c Department of Ophthalmology and Inha Vision Science Laboratory, Inha University School of Medicine, Incheon, South Korea 
d Department of Ophthalmology, Prince Mohammad Bin Abdulaziz Hospital, Riyadh, Saudi Arabia 
e Stulting Research Center, Woolfson Eye Institute, Atlanta, Georgia, USA 
f Department of Ophthalmology and Cornea Service, University of California San Francisco, San Francisco, California, USA 

Inquiries to Kyoung Yul Seo, Department of Ophthalmology, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul, South Korea, 120-752Department of OphthalmologyYonsei University College of Medicine50 Yonsei-ro, Seodaemun-guSeoul120-752South Korea

Abstract

Purpose

To report cases of necrotizing scleritis, a sight-threatening complication that can result from cosmetic conjunctivectomy procedures.

Design

Retrospective case series.

Methods

The medical records of consecutive patients who underwent eye-whitening conjunctivectomy with mitoycin C (MMC) treatment performed by 1 surgeon in South Korea and were referred to the authors' clinic between January 2011 and December 2015 were reviewed. The patients in whom findings of necrotizing scleritis with active inflammation were detected in an avascular area of previous conjunctivectomy were included.

Results

Of a total of 231 patients who had received cosmetic eye whitening, 4 patients who met the inclusion criteria were identified. The average length of time from cosmetic eye surgery to a diagnosis of necrotizing scleritis was 51 months and all patients had unilateral findings of necrotizing scleritis. There was no underlying systemic autoimmunity or infectious etiology in all cases. Three of these 4 patients were treated with a conjunctival flap; however, all 4 received systemic anti-inflammatory treatment with oral corticosteroids. The mean follow-up duration of the patients was 22.75 months.

Conclusions

Necrotizing scleritis is a severe complication that can arise after cosmetic eye-whitening conjunctivectomy with MMC. Because of the large area of the ocular surface that is treated in eye-whitening with MMC, the necrotizing scleritis that can ensue may be more extensive and severe than the surgically induced necrotizing scleritis following other periocular surgeries such as pterygium removal. Proper anti-inflammatory treatment and surgical intervention should be required for management of this complication.

Il testo completo di questo articolo è disponibile in PDF.

Mappa


 Supplemental Material available at AJO.com.


© 2018  Elsevier Inc. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 194

P. 72-81 - ottobre 2018 Ritorno al numero
Articolo precedente Articolo precedente
  • Treatment Duration and Side Effect Profile of Long-Term Use of Intravitreal Preservative-Free Triamcinolone Acetonide in Uveitis
  • Preethi S. Ganapathy, Careen Y. Lowder, Sruthi Arepalli, Kimberly Baynes, Manshi Li, James Bena, Sunil K. Srivastava
| Articolo seguente Articolo seguente
  • Serum Angiotensin-Converting Enzyme Has a High Negative Predictive Value in the Investigation for Systemic Sarcoidosis
  • Rachael L. Niederer, Ahmed Al-Janabi, Sue L. Lightman, Oren Tomkins-Netzer

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.